Home • Search • Translate
From Wikipedia, the free encyclopedia

Ziyad Al-Aly is an American physician and clinical epidemiologist who is currently Director of the Clinical Epidemiology Center and Chief of the Research and Development at the Veterans Affairs St. Louis Health Care System. [1] [2] [3] He is also a clinical epidemiologist at Washington University in St. Louis. [2] He has led multiple studies on long covid and its sequelae. [4]

Early life

Al-Aly was born in Tripoli, Lebanon to teachers. [5] He grew up during the Lebanese civil war which dominated Lebanon from 1975 to 1990, [5] emigrating to the United States in 2000.

Education

Al-Aly holds a medical degree from the American University of Beirut. [6] He completed his post-graduate medical education at Saint Louis University and Washington University in St. Louis.

Career

Al-Aly's research work has been cited more than a 100,000 times and he has an h-index of more than 79 according to Google Scholar. [7]

Long COVID research

Al-Aly led work which provided the first systematic characterization of the post-acute sequelae of SARS-CoV-2 infection. [8] He subsequently led work which characterized the increased risks of cardiovascular disease, [9] neurologic disorders, [10] mental health disorders, [11] gastrointestinal disorders, [12] diabetes, [13] dyslipidemia, [14] and kidney disease [15] following SARS-CoV-2 infection. His lab also produced evidence characterizing the effects of COVID-19 vaccines on long COVID [16] and the health consequences of repeated infections with SARS-CoV-2. [17]

In 2024, Al-Aly testified before the U.S. Senate Health, Education, Labor and Pensions Committee as an expert witness on Long Covid. He called for the establishment of an NIH institute to address Long Covid and Infection-Associated Chronic Conditions (IACCs) — also called post-acute infection syndrome — with a funding of at least $1 billion per year. [18]

Pharmacoepidemiology

Including work characterizing the adverse health effect of proton pump inhibitors and comparative effectiveness of antihyperglycemic medications. His work also included examining the effectiveness of COVID-19 antivirals including paxlovid (nirmatrelvir/ritonavir) and molnupiravir on acute COVID-19 outcomes [19] [20] and long COVID. [21] [22]

Environmental epidemiology research

Including work which evaluated the effect of air pollution on kidney health, [23] diabetes, [24] and early mortality. [25]

Honors and awards

In 2023, Al-Aly was awarded the U.S. Department of Veterans Affairs Secretary's Award — the highest VA award — for outstanding contributions to research.

References

  1. ^ "Repeat coronavirus infections can still be dangerous, study suggests". The Washington Post. Retrieved 11 November 2022.
  2. ^ a b "Ziyad Al-Aly, MD". Washington University in St. Louis. Retrieved 11 November 2022.
  3. ^ Outlook Magazine, Washington University in Saint Louis (2023-06-21). "Real-world reflections". Outlook Magazine. Retrieved 2023-08-03.
  4. ^ "COVID-19 infections increase risk of long-term brain problems". Washington University in St. Louis. 22 September 2022. Retrieved 11 November 2022.
  5. ^ a b Outlook Magazine, Washington University in Saint Louis (2023-06-21). "Real-world reflections". Outlook Magazine. Retrieved 2023-08-05.
  6. ^ "Ziyad Al-Aly, MD, FASN". Washington University in St. Louis. Retrieved 11 November 2022.
  7. ^ "Ziyad Al-Aly, MD". Google Scholar. Retrieved 11 January 2024.
  8. ^ Al-Aly, Ziyad; Xie, Yan; Bowe, Benjamin (June 2021). "High-dimensional characterization of post-acute sequelae of COVID-19". Nature. 594 (7862): 259–264. Bibcode: 2021Natur.594..259A. doi: 10.1038/s41586-021-03553-9. ISSN  1476-4687. PMID  33887749. S2CID  233373053.
  9. ^ Xie, Yan; Xu, Evan; Bowe, Benjamin; Al-Aly, Ziyad (March 2022). "Long-term cardiovascular outcomes of COVID-19". Nature Medicine. 28 (3): 583–590. doi: 10.1038/s41591-022-01689-3. ISSN  1546-170X. PMC  8938267. PMID  35132265.
  10. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (November 2022). "Long-term neurologic outcomes of COVID-19". Nature Medicine. 28 (11): 2406–2415. doi: 10.1038/s41591-022-02001-z. ISSN  1546-170X. PMC  9671811. PMID  36138154.
  11. ^ Xie, Yan; Xu, Evan; Al-Aly, Ziyad (2022-02-16). "Risks of mental health outcomes in people with covid-19: cohort study". BMJ. 376: e068993. doi: 10.1136/bmj-2021-068993. ISSN  1756-1833. PMC  8847881. PMID  35172971.
  12. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (2023-03-07). "Long-term gastrointestinal outcomes of COVID-19". Nature Communications. 14 (1): 983. Bibcode: 2023NatCo..14..983X. doi: 10.1038/s41467-023-36223-7. ISSN  2041-1723. PMC  9992516. PMID  36882400.
  13. ^ Xie, Yan; Al-Aly, Ziyad (2022-05-01). "Risks and burdens of incident diabetes in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 10 (5): 311–321. doi: 10.1016/S2213-8587(22)00044-4. ISSN  2213-8587. PMC  8937253. PMID  35325624.
  14. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (2023-02-01). "Risks and burdens of incident dyslipidaemia in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 11 (2): 120–128. doi: 10.1016/S2213-8587(22)00355-2. ISSN  2213-8587. PMC  9873268. PMID  36623520.
  15. ^ Bowe, Benjamin; Xie, Yan; Xu, Evan; Al-Aly, Ziyad (November 2021). "Kidney Outcomes in Long COVID". Journal of the American Society of Nephrology. 32 (11): 2851–2862. doi: 10.1681/ASN.2021060734. ISSN  1046-6673. PMC  8806085. PMID  34470828. S2CID  237389462.
  16. ^ Al-Aly, Ziyad; Bowe, Benjamin; Xie, Yan (July 2022). "Long COVID after breakthrough SARS-CoV-2 infection". Nature Medicine. 28 (7): 1461–1467. doi: 10.1038/s41591-022-01840-0. ISSN  1546-170X. PMC  9307472. PMID  35614233.
  17. ^ Bowe, Benjamin; Xie, Yan; Al-Aly, Ziyad (November 2022). "Acute and postacute sequelae associated with SARS-CoV-2 reinfection". Nature Medicine. 28 (11): 2398–2405. doi: 10.1038/s41591-022-02051-3. ISSN  1546-170X. PMC  9671810. PMID  36357676.
  18. ^ "Testimony of Ziyad Al-Aly, M.D., Clinical Epidemiologist, Washington University in Saint Louis, Saint Louis, MO Before United States Senate Committee on Health, Education, Labor and Pensions" (PDF). U.S. Senate Committee on Health, Education, Labor and Pensions. January 18, 2024. Archived from the original (PDF) on 2024-01-18.
  19. ^ Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad (2023-04-11). "Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records". BMJ. 381: e073312. doi: 10.1136/bmj-2022-073312. ISSN  1756-1833. PMC  10086514. PMID  37041016.
  20. ^ Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad (2023-03-07). "Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records". BMJ. 380: e072705. doi: 10.1136/bmj-2022-072705. ISSN  1756-1833. PMC  9989554. PMID  36882199.
  21. ^ Xie, Yan; Choi, Taeyoung; Al-Aly, Ziyad (2023-06-01). "Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition". JAMA Internal Medicine. 183 (6): 554–564. doi: 10.1001/jamainternmed.2023.0743. ISSN  2168-6106. PMC  10037200. PMID  36951829.
  22. ^ Xie, Yan; Choi, Taeyoung; Al-Aly, Ziyad (2023-04-25). "Molnupiravir and risk of post-acute sequelae of covid-19: cohort study". BMJ. 381: e074572. doi: 10.1136/bmj-2022-074572. ISSN  1756-1833. PMC  10126525. PMID  37161995.
  23. ^ Bowe, Benjamin; Xie, Yan; Li, Tingting; Yan, Yan; Xian, Hong; Al-Aly, Ziyad (January 2018). "Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD". Journal of the American Society of Nephrology. 29 (1): 218–230. doi: 10.1681/ASN.2017030253. ISSN  1046-6673. PMC  5748906. PMID  28935655.
  24. ^ Bowe, Benjamin; Xie, Yan; Li, Tingting; Yan, Yan; Xian, Hong; Al-Aly, Ziyad (July 2018). "The 2016 global and national burden of diabetes mellitus attributable to PM 2·5 air pollution". The Lancet Planetary Health. 2 (7): e301–e312. doi: 10.1016/s2542-5196(18)30140-2. ISSN  2542-5196. PMID  30074893.
  25. ^ Bowe, Benjamin; Xie, Yan; Yan, Yan; Al-Aly, Ziyad (2019-11-20). "Burden of Cause-Specific Mortality Associated With PM 2.5 Air Pollution in the United States". JAMA Network Open. 2 (11): e1915834. doi: 10.1001/jamanetworkopen.2019.15834. ISSN  2574-3805. PMC  6902821. PMID  31747037.

External links

Retrieved from " https://en.wikipedia.org/?title=Ziyad_Al-Aly&oldid=1216102110"
From Wikipedia, the free encyclopedia

Ziyad Al-Aly is an American physician and clinical epidemiologist who is currently Director of the Clinical Epidemiology Center and Chief of the Research and Development at the Veterans Affairs St. Louis Health Care System. [1] [2] [3] He is also a clinical epidemiologist at Washington University in St. Louis. [2] He has led multiple studies on long covid and its sequelae. [4]

Early life

Al-Aly was born in Tripoli, Lebanon to teachers. [5] He grew up during the Lebanese civil war which dominated Lebanon from 1975 to 1990, [5] emigrating to the United States in 2000.

Education

Al-Aly holds a medical degree from the American University of Beirut. [6] He completed his post-graduate medical education at Saint Louis University and Washington University in St. Louis.

Career

Al-Aly's research work has been cited more than a 100,000 times and he has an h-index of more than 79 according to Google Scholar. [7]

Long COVID research

Al-Aly led work which provided the first systematic characterization of the post-acute sequelae of SARS-CoV-2 infection. [8] He subsequently led work which characterized the increased risks of cardiovascular disease, [9] neurologic disorders, [10] mental health disorders, [11] gastrointestinal disorders, [12] diabetes, [13] dyslipidemia, [14] and kidney disease [15] following SARS-CoV-2 infection. His lab also produced evidence characterizing the effects of COVID-19 vaccines on long COVID [16] and the health consequences of repeated infections with SARS-CoV-2. [17]

In 2024, Al-Aly testified before the U.S. Senate Health, Education, Labor and Pensions Committee as an expert witness on Long Covid. He called for the establishment of an NIH institute to address Long Covid and Infection-Associated Chronic Conditions (IACCs) — also called post-acute infection syndrome — with a funding of at least $1 billion per year. [18]

Pharmacoepidemiology

Including work characterizing the adverse health effect of proton pump inhibitors and comparative effectiveness of antihyperglycemic medications. His work also included examining the effectiveness of COVID-19 antivirals including paxlovid (nirmatrelvir/ritonavir) and molnupiravir on acute COVID-19 outcomes [19] [20] and long COVID. [21] [22]

Environmental epidemiology research

Including work which evaluated the effect of air pollution on kidney health, [23] diabetes, [24] and early mortality. [25]

Honors and awards

In 2023, Al-Aly was awarded the U.S. Department of Veterans Affairs Secretary's Award — the highest VA award — for outstanding contributions to research.

References

  1. ^ "Repeat coronavirus infections can still be dangerous, study suggests". The Washington Post. Retrieved 11 November 2022.
  2. ^ a b "Ziyad Al-Aly, MD". Washington University in St. Louis. Retrieved 11 November 2022.
  3. ^ Outlook Magazine, Washington University in Saint Louis (2023-06-21). "Real-world reflections". Outlook Magazine. Retrieved 2023-08-03.
  4. ^ "COVID-19 infections increase risk of long-term brain problems". Washington University in St. Louis. 22 September 2022. Retrieved 11 November 2022.
  5. ^ a b Outlook Magazine, Washington University in Saint Louis (2023-06-21). "Real-world reflections". Outlook Magazine. Retrieved 2023-08-05.
  6. ^ "Ziyad Al-Aly, MD, FASN". Washington University in St. Louis. Retrieved 11 November 2022.
  7. ^ "Ziyad Al-Aly, MD". Google Scholar. Retrieved 11 January 2024.
  8. ^ Al-Aly, Ziyad; Xie, Yan; Bowe, Benjamin (June 2021). "High-dimensional characterization of post-acute sequelae of COVID-19". Nature. 594 (7862): 259–264. Bibcode: 2021Natur.594..259A. doi: 10.1038/s41586-021-03553-9. ISSN  1476-4687. PMID  33887749. S2CID  233373053.
  9. ^ Xie, Yan; Xu, Evan; Bowe, Benjamin; Al-Aly, Ziyad (March 2022). "Long-term cardiovascular outcomes of COVID-19". Nature Medicine. 28 (3): 583–590. doi: 10.1038/s41591-022-01689-3. ISSN  1546-170X. PMC  8938267. PMID  35132265.
  10. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (November 2022). "Long-term neurologic outcomes of COVID-19". Nature Medicine. 28 (11): 2406–2415. doi: 10.1038/s41591-022-02001-z. ISSN  1546-170X. PMC  9671811. PMID  36138154.
  11. ^ Xie, Yan; Xu, Evan; Al-Aly, Ziyad (2022-02-16). "Risks of mental health outcomes in people with covid-19: cohort study". BMJ. 376: e068993. doi: 10.1136/bmj-2021-068993. ISSN  1756-1833. PMC  8847881. PMID  35172971.
  12. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (2023-03-07). "Long-term gastrointestinal outcomes of COVID-19". Nature Communications. 14 (1): 983. Bibcode: 2023NatCo..14..983X. doi: 10.1038/s41467-023-36223-7. ISSN  2041-1723. PMC  9992516. PMID  36882400.
  13. ^ Xie, Yan; Al-Aly, Ziyad (2022-05-01). "Risks and burdens of incident diabetes in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 10 (5): 311–321. doi: 10.1016/S2213-8587(22)00044-4. ISSN  2213-8587. PMC  8937253. PMID  35325624.
  14. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (2023-02-01). "Risks and burdens of incident dyslipidaemia in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 11 (2): 120–128. doi: 10.1016/S2213-8587(22)00355-2. ISSN  2213-8587. PMC  9873268. PMID  36623520.
  15. ^ Bowe, Benjamin; Xie, Yan; Xu, Evan; Al-Aly, Ziyad (November 2021). "Kidney Outcomes in Long COVID". Journal of the American Society of Nephrology. 32 (11): 2851–2862. doi: 10.1681/ASN.2021060734. ISSN  1046-6673. PMC  8806085. PMID  34470828. S2CID  237389462.
  16. ^ Al-Aly, Ziyad; Bowe, Benjamin; Xie, Yan (July 2022). "Long COVID after breakthrough SARS-CoV-2 infection". Nature Medicine. 28 (7): 1461–1467. doi: 10.1038/s41591-022-01840-0. ISSN  1546-170X. PMC  9307472. PMID  35614233.
  17. ^ Bowe, Benjamin; Xie, Yan; Al-Aly, Ziyad (November 2022). "Acute and postacute sequelae associated with SARS-CoV-2 reinfection". Nature Medicine. 28 (11): 2398–2405. doi: 10.1038/s41591-022-02051-3. ISSN  1546-170X. PMC  9671810. PMID  36357676.
  18. ^ "Testimony of Ziyad Al-Aly, M.D., Clinical Epidemiologist, Washington University in Saint Louis, Saint Louis, MO Before United States Senate Committee on Health, Education, Labor and Pensions" (PDF). U.S. Senate Committee on Health, Education, Labor and Pensions. January 18, 2024. Archived from the original (PDF) on 2024-01-18.
  19. ^ Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad (2023-04-11). "Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records". BMJ. 381: e073312. doi: 10.1136/bmj-2022-073312. ISSN  1756-1833. PMC  10086514. PMID  37041016.
  20. ^ Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad (2023-03-07). "Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records". BMJ. 380: e072705. doi: 10.1136/bmj-2022-072705. ISSN  1756-1833. PMC  9989554. PMID  36882199.
  21. ^ Xie, Yan; Choi, Taeyoung; Al-Aly, Ziyad (2023-06-01). "Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition". JAMA Internal Medicine. 183 (6): 554–564. doi: 10.1001/jamainternmed.2023.0743. ISSN  2168-6106. PMC  10037200. PMID  36951829.
  22. ^ Xie, Yan; Choi, Taeyoung; Al-Aly, Ziyad (2023-04-25). "Molnupiravir and risk of post-acute sequelae of covid-19: cohort study". BMJ. 381: e074572. doi: 10.1136/bmj-2022-074572. ISSN  1756-1833. PMC  10126525. PMID  37161995.
  23. ^ Bowe, Benjamin; Xie, Yan; Li, Tingting; Yan, Yan; Xian, Hong; Al-Aly, Ziyad (January 2018). "Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD". Journal of the American Society of Nephrology. 29 (1): 218–230. doi: 10.1681/ASN.2017030253. ISSN  1046-6673. PMC  5748906. PMID  28935655.
  24. ^ Bowe, Benjamin; Xie, Yan; Li, Tingting; Yan, Yan; Xian, Hong; Al-Aly, Ziyad (July 2018). "The 2016 global and national burden of diabetes mellitus attributable to PM 2·5 air pollution". The Lancet Planetary Health. 2 (7): e301–e312. doi: 10.1016/s2542-5196(18)30140-2. ISSN  2542-5196. PMID  30074893.
  25. ^ Bowe, Benjamin; Xie, Yan; Yan, Yan; Al-Aly, Ziyad (2019-11-20). "Burden of Cause-Specific Mortality Associated With PM 2.5 Air Pollution in the United States". JAMA Network Open. 2 (11): e1915834. doi: 10.1001/jamanetworkopen.2019.15834. ISSN  2574-3805. PMC  6902821. PMID  31747037.

External links

Retrieved from " https://en.wikipedia.org/?title=Ziyad_Al-Aly&oldid=1216102110"

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook




Top Of Page

Home • Search • Translate

© CSE